中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2011年
7期
618-620
,共3页
舒尼替尼%恶性胰岛细胞瘤
舒尼替尼%噁性胰島細胞瘤
서니체니%악성이도세포류
Sunitinib malate%Malignant islet cell tumor
恶性胰岛细胞瘤是一种少见但治疗效果欠佳的神经内分泌肿瘤.舒尼替尼作为新一代的酪氨酸激酶抑制剂,已被证实对于恶性胰岛细胞瘤具备较好的疗效.
噁性胰島細胞瘤是一種少見但治療效果欠佳的神經內分泌腫瘤.舒尼替尼作為新一代的酪氨痠激酶抑製劑,已被證實對于噁性胰島細胞瘤具備較好的療效.
악성이도세포류시일충소견단치료효과흠가적신경내분비종류.서니체니작위신일대적락안산격매억제제,이피증실대우악성이도세포류구비교호적료효.
Malignant islet cell tumor, a rare type of neuroendocrine carcinoma, biologically behaves in an aggressive way and is difficulty to be treated. Sunitinib malate, a novel tyrosine kinase inhibitor, demonstrates a high efficacy in treating malignant islet cell tumor as shown by promising results in recent trials.
